151. Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension

Category Primary study
JournalMultiple Sclerosis and Related Disorders
Year 2024
This article has no abstract
Epistemonikos ID: d1cac90a359b42a12019308978862b60ae31ed8d
First added on: Feb 19, 2025